NKTR Drug delivery Company Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company

NKTR 59.58

+5.1%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: david nordic who wrote (8)	12/22/2005 1:15:20 PM
From: tuck	Read Replies (2) of 507

>>WASHINGTON (Dow Jones)--Nektar Therapeutics (NKTR) registered to sell $315 million of its 3.25% convertible subordinated notes due 2012 for some noteholders from time to time under a Form S-3 filed with the Securities and Exchange Commission. The San Carlos, Calif., company said it issued the convertible notes in a private offering Sept. 28. Nektar Therapeutics said it won't receive any proceeds from the resale of the convertible notes. The company reported in a Sept. 22 press release that the notes are convertible into common shares of Nektar Therapeutics at an initial conversion rate of 46.4727 shares per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $21.52 a share. Nektar Therapeutics develops drug delivery systems to deliver drugs, including peptides, proteins and other molecules, by inhalation deep into the lung to treat systemic and respiratory diseases. << Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next